IDEAYA Biosciences, Inc.
NASDAQ:IDYABiotechnology
-$0.45 today
- Market cap
- $2.56B
- Beta
- -0.05
- P/E (TTM)
- -19.5
- EPS (TTM)
- -$1.58
Volume 1.45M
Average 1.44M
IDYA Stock-Based Compensation
Employee pay granted in shares or options; a non-cash expense that dilutes existing shareholders.
IDEAYA Biosciences, Inc.NASDAQ: IDYA
Stock-Based Compensation · Q1 FY2026 · quarter ended Mar 2026
Stock-based compensation growth accelerates
Q1 FY2026 stock-based compensation of $14.54M rose 42.0% year over year, ahead of the +30.4% change in trailing-twelve-month stock-based compensation. Sequentially, it rose 23.3% from the prior quarter. Over 3 fiscal years it compounded at +58.3% a year.
Context
- Stock-based compensation amounted to 21.1% of revenue in FY2025, down 475.3 pp from a year earlier.
- Stock-based compensation increased in 3 of the last 3 fiscal years.
- FY2025 was the highest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +42.0% holds above the trailing-twelve-month pace of +30.4%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Stock-Based Compensation history
USD · from the cash flow
- Latest · FY2025
- 46.12M USD
- Year-over-year change
- +32.7%
- 4-year CAGR
- +53.8%
| Period | Period end | Stock-Based Compensation | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | 46.12M | +32.7% |
| FY2024 | 2024-12-31 | 34.75M | +87.9% |
| FY2023 | 2023-12-31 | 18.49M | +59.0% |
| FY2022 | 2022-12-31 | 11.63M | +41.2% |
| FY2021 | 2021-12-31 | 8.24M | — |
Stock-Based Compensation vs competitors
How IDYA compares with its peers on the latest reported figures
- IDYA's LTM Mar 2026 stock-based compensation of $50.41M is the 4th largest of the 9 companies compared; the peer median is $38.24M.
- Its year-over-year change of +30.4% is the 6th highest of 9, against a peer median of +41.6%.
- Stock-based compensation amounts to 22.4% of revenue for IDYA, versus a peer median of 22.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Jun 2026 | $151.77M | +56.3% | +56.0% | — | |
| LTM Jun 2026 | $60.37M | +50.7% | +35.9% | — | |
| LTM Sep 2026 | $58.58M | +109.9% | +22.9% | — | |
| LTM Mar 2026 | $50.41M | +30.4% | +58.3% | 22.4% | |
| LTM Aug 2026 | $40.66M | +8.7% | +10.5% | 5.8% | |
| LTM Sep 2026 | $35.82M | +41.1% | +7.4% | — | |
| LTM Mar 2026 | $10.08M | -60.8% | -22.0% | 60.3% | |
| LTM Mar 2026 | $9.66M | +26.4% | +15.9% | 19.5% | |
| LTM Mar 2026 | $7.36M | +42.2% | — | 26.1% | |
| Peer median (excluding IDYA) | $38.24M | +41.6% | +15.9% | 22.8% | |
Competitors are the stored peer set for IDYA. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (49.76M) | (58.66M) | (112.96M) | (274.48M) | (113.7M) |
| Depreciation & Amortization | 1.73M | 2.1M | 4.01M | 3.83M | 4.59M |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 8.24M | 11.63M | 18.49M | 34.75M | 46.12M |
| Change in Working Capital | (17.81M) | (41.56M) | (13.21M) | 11.55M | 1.87M |
| Accounts Receivables | 774K | 892K | 193K | 15K | 0 |
| Inventory | 3.79M | 0 | 0 | 0 | 0 |
| Accounts Payables | 1.17M | 1.86M | 2.64M | 8.28M | 2.7M |
| Other Working Capital | (23.54M) | (44.31M) | (16.04M) | 3.25M | (829K) |
| Other Non-Cash Items | 1.83M | (695K) | (11.55M) | (23.23M) | (9.98M) |
| Operating Cash Flow | (55.78M) | (87.18M) | (115.22M) | (247.58M) | (71.1M) |
| Capital Expenditures | (2.64M) | (3.44M) | (2.37M) | (3.86M) | (2.37M) |
| Acquisitions (Net) | 67.02M | 33.4M | 0 | 0 | 0 |
| Purchases of Investments | (315M) | (255.81M) | (595.98M) | (1.19B) | (607.89M) |
| Sales of Investments | 247.97M | 225.85M | 439.89M | 692.61M | 680.23M |
| Other Investing Activities | (67.02M) | (33.4M) | 0 | 0 | 0 |
| Investing Cash Flow | (69.67M) | (33.4M) | (158.46M) | (502.56M) | 69.98M |
| Debt Repayment | 0 | 0 | 0 | 0 | 0 |
| Common Stock Issued | 143.25M | 94.96M | 309.76M | 654.23M | 29.78M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | 2.2M | 2.2M | 10.77M | 13.92M | 0 |
| Financing Cash Flow | 145.45M | 97.17M | 362.72M | 677.55M | 29.78M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | (210K) |
| Net Change in Cash | 20.01M | (23.41M) | 89.04M | (72.59M) | 28.45M |
| Free Cash Flow | (58.42M) | (90.62M) | (117.59M) | (251.44M) | (73.47M) |
IDEAYA Biosciences, Inc.
NASDAQ:IDYA
Intrinsic Alpha fair value
Locked
Current Price
$26.49
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.